Recognition of early mortality in multiple myeloma by a prediction matrix

Howard Terebelo, Shankar Srinivasan, Mohit Narang, Rafat Abonour, Cristina Gasparetto, Kathleen Toomey, James W. Hardin, Gail Larkins, Amani Kitali, Robert M. Rifkin, Jatin J. Shah

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Early mortality (EM; death ≤ 6 months from diagnosis) has been reported in several newly diagnosed multiple myeloma (NDMM) trials. Before the era of novel agents, the incidence was 10%-14%. Causes of death included infections/pneumonia, renal failure, refractory disease, and cardiac events. Staging systems, such as the revised International Staging System (r-ISS), and prognostic factors including cytogenetics, lactate dehydrogenase levels, and myeloma-specific factors, are useful to assess overall prognosis; however, they cannot predict EM. We evaluated patients treated with novel agents in the Connect MM® Registry and identified risk factors of the EM cohort. Eligible patients were enrolled in the registry within 60 days of diagnosis. Univariate and multivariate analyses were conducted to evaluate associations between baseline characteristics and EM. Prediction matrices for EM were constructed from a logistic model. Between September 2009 and December 2011, 1493 patients were enrolled in the registry and had adequate follow-up. Of these patients, 102 (6.8%) had EM and 1391 (93.2%) survived for > 180 days. Baseline factors significantly associated with increased EM risk included age > 75 years, higher Eastern Cooperative Oncology Group performance status, lower EQ-5D mobility score, higher ISS stage, lower platelet count, and prior hypertension. Renal insufficiency trended toward increased EM risk. These risk factors were incorporated into a prediction matrix for EM. The EM prediction matrix uses differential weighting of risk factors to calculate EM risk in patients with NDMM. Identifying patients at risk for EM may provide new opportunities to implement patient-specific treatment strategies to improve outcomes.

Original languageEnglish (US)
Pages (from-to)915-923
Number of pages9
JournalAmerican Journal of Hematology
Volume92
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Multiple Myeloma
Mortality
Registries
Renal Insufficiency
Injury Severity Score
Platelet Count
L-Lactate Dehydrogenase
Cytogenetics
Cause of Death
Heart Diseases
Pneumonia
Multivariate Analysis
Logistic Models
Hypertension
Incidence
Infection

ASJC Scopus subject areas

  • Hematology

Cite this

Terebelo, H., Srinivasan, S., Narang, M., Abonour, R., Gasparetto, C., Toomey, K., ... Shah, J. J. (2017). Recognition of early mortality in multiple myeloma by a prediction matrix. American Journal of Hematology, 92(9), 915-923. https://doi.org/10.1002/ajh.24796

Recognition of early mortality in multiple myeloma by a prediction matrix. / Terebelo, Howard; Srinivasan, Shankar; Narang, Mohit; Abonour, Rafat; Gasparetto, Cristina; Toomey, Kathleen; Hardin, James W.; Larkins, Gail; Kitali, Amani; Rifkin, Robert M.; Shah, Jatin J.

In: American Journal of Hematology, Vol. 92, No. 9, 01.09.2017, p. 915-923.

Research output: Contribution to journalArticle

Terebelo, H, Srinivasan, S, Narang, M, Abonour, R, Gasparetto, C, Toomey, K, Hardin, JW, Larkins, G, Kitali, A, Rifkin, RM & Shah, JJ 2017, 'Recognition of early mortality in multiple myeloma by a prediction matrix', American Journal of Hematology, vol. 92, no. 9, pp. 915-923. https://doi.org/10.1002/ajh.24796
Terebelo, Howard ; Srinivasan, Shankar ; Narang, Mohit ; Abonour, Rafat ; Gasparetto, Cristina ; Toomey, Kathleen ; Hardin, James W. ; Larkins, Gail ; Kitali, Amani ; Rifkin, Robert M. ; Shah, Jatin J. / Recognition of early mortality in multiple myeloma by a prediction matrix. In: American Journal of Hematology. 2017 ; Vol. 92, No. 9. pp. 915-923.
@article{bca19b12ae7144f28fd03ab38955bda7,
title = "Recognition of early mortality in multiple myeloma by a prediction matrix",
abstract = "Early mortality (EM; death ≤ 6 months from diagnosis) has been reported in several newly diagnosed multiple myeloma (NDMM) trials. Before the era of novel agents, the incidence was 10{\%}-14{\%}. Causes of death included infections/pneumonia, renal failure, refractory disease, and cardiac events. Staging systems, such as the revised International Staging System (r-ISS), and prognostic factors including cytogenetics, lactate dehydrogenase levels, and myeloma-specific factors, are useful to assess overall prognosis; however, they cannot predict EM. We evaluated patients treated with novel agents in the Connect MM{\circledR} Registry and identified risk factors of the EM cohort. Eligible patients were enrolled in the registry within 60 days of diagnosis. Univariate and multivariate analyses were conducted to evaluate associations between baseline characteristics and EM. Prediction matrices for EM were constructed from a logistic model. Between September 2009 and December 2011, 1493 patients were enrolled in the registry and had adequate follow-up. Of these patients, 102 (6.8{\%}) had EM and 1391 (93.2{\%}) survived for > 180 days. Baseline factors significantly associated with increased EM risk included age > 75 years, higher Eastern Cooperative Oncology Group performance status, lower EQ-5D mobility score, higher ISS stage, lower platelet count, and prior hypertension. Renal insufficiency trended toward increased EM risk. These risk factors were incorporated into a prediction matrix for EM. The EM prediction matrix uses differential weighting of risk factors to calculate EM risk in patients with NDMM. Identifying patients at risk for EM may provide new opportunities to implement patient-specific treatment strategies to improve outcomes.",
author = "Howard Terebelo and Shankar Srinivasan and Mohit Narang and Rafat Abonour and Cristina Gasparetto and Kathleen Toomey and Hardin, {James W.} and Gail Larkins and Amani Kitali and Rifkin, {Robert M.} and Shah, {Jatin J.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1002/ajh.24796",
language = "English (US)",
volume = "92",
pages = "915--923",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Recognition of early mortality in multiple myeloma by a prediction matrix

AU - Terebelo, Howard

AU - Srinivasan, Shankar

AU - Narang, Mohit

AU - Abonour, Rafat

AU - Gasparetto, Cristina

AU - Toomey, Kathleen

AU - Hardin, James W.

AU - Larkins, Gail

AU - Kitali, Amani

AU - Rifkin, Robert M.

AU - Shah, Jatin J.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Early mortality (EM; death ≤ 6 months from diagnosis) has been reported in several newly diagnosed multiple myeloma (NDMM) trials. Before the era of novel agents, the incidence was 10%-14%. Causes of death included infections/pneumonia, renal failure, refractory disease, and cardiac events. Staging systems, such as the revised International Staging System (r-ISS), and prognostic factors including cytogenetics, lactate dehydrogenase levels, and myeloma-specific factors, are useful to assess overall prognosis; however, they cannot predict EM. We evaluated patients treated with novel agents in the Connect MM® Registry and identified risk factors of the EM cohort. Eligible patients were enrolled in the registry within 60 days of diagnosis. Univariate and multivariate analyses were conducted to evaluate associations between baseline characteristics and EM. Prediction matrices for EM were constructed from a logistic model. Between September 2009 and December 2011, 1493 patients were enrolled in the registry and had adequate follow-up. Of these patients, 102 (6.8%) had EM and 1391 (93.2%) survived for > 180 days. Baseline factors significantly associated with increased EM risk included age > 75 years, higher Eastern Cooperative Oncology Group performance status, lower EQ-5D mobility score, higher ISS stage, lower platelet count, and prior hypertension. Renal insufficiency trended toward increased EM risk. These risk factors were incorporated into a prediction matrix for EM. The EM prediction matrix uses differential weighting of risk factors to calculate EM risk in patients with NDMM. Identifying patients at risk for EM may provide new opportunities to implement patient-specific treatment strategies to improve outcomes.

AB - Early mortality (EM; death ≤ 6 months from diagnosis) has been reported in several newly diagnosed multiple myeloma (NDMM) trials. Before the era of novel agents, the incidence was 10%-14%. Causes of death included infections/pneumonia, renal failure, refractory disease, and cardiac events. Staging systems, such as the revised International Staging System (r-ISS), and prognostic factors including cytogenetics, lactate dehydrogenase levels, and myeloma-specific factors, are useful to assess overall prognosis; however, they cannot predict EM. We evaluated patients treated with novel agents in the Connect MM® Registry and identified risk factors of the EM cohort. Eligible patients were enrolled in the registry within 60 days of diagnosis. Univariate and multivariate analyses were conducted to evaluate associations between baseline characteristics and EM. Prediction matrices for EM were constructed from a logistic model. Between September 2009 and December 2011, 1493 patients were enrolled in the registry and had adequate follow-up. Of these patients, 102 (6.8%) had EM and 1391 (93.2%) survived for > 180 days. Baseline factors significantly associated with increased EM risk included age > 75 years, higher Eastern Cooperative Oncology Group performance status, lower EQ-5D mobility score, higher ISS stage, lower platelet count, and prior hypertension. Renal insufficiency trended toward increased EM risk. These risk factors were incorporated into a prediction matrix for EM. The EM prediction matrix uses differential weighting of risk factors to calculate EM risk in patients with NDMM. Identifying patients at risk for EM may provide new opportunities to implement patient-specific treatment strategies to improve outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85025127562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025127562&partnerID=8YFLogxK

U2 - 10.1002/ajh.24796

DO - 10.1002/ajh.24796

M3 - Article

C2 - 28543165

AN - SCOPUS:85025127562

VL - 92

SP - 915

EP - 923

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 9

ER -